Scios News

Just recently, an FDA Panel narrowly ruled against the prescription of Johnson & Johnson and Bayer 's blood-thinning drug Xarelto for patients with serious heart problems.

The Food and Drug Administration is warning a Johnson & Johnson unit that it failed to look into dozens of consumer complaints about its K-Y Liquibeads Vaginal Moisturizer and other products in the last two years.

Johnson & Johnson is celebrating its 10-year anniversary of the Campaign for Nursing's Future via a new mobile site that aims to inform, connect and educate current and prospective nurses across the country.

Hedge funds turned their backs on Johnson & Johnson and Amazon.com Inc in the last months, kicking the former market darlings into a group where they see stock prices dropping, research from Goldman Sachs shows.

Johnson & Johnson is a sound defensive investment for any conservative investors interested in the long term.

Since my last article in February about Myrexis we have seen a small pop in the share price and a subsequent drop as well.

The Food and Drug Administration says a blood thinner from Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of internal bleeding.

Johnson & Johnson and Bayer AG's blood-thinner Xarelto should be approved to help prevent heart attacks and strokes in patients with a common condition, a U.S. regulatory report recommended.

In fact, during the past 10 days, speculators on the major options exchanges have sold to open 6.3 times more puts than they have purchased.

Linked here is a detailed quantitative analysis of Johnson & Johnson . Below are some highlights from the above linked analysis: Company Description: Johnson & Johnson is a leader in the pharmaceutical, medical device and consumer products industries.

Johnson & Johnson is "very serious" about acquiring assets in China to treat conditions such as mental disease and cancer, to help it match or outpace growth in the country's pharmaceuticals market, an executive said.

Groundbreaking new research is allowing quadriplegics to control objects with a robotic arm and the power of their thoughts.

Let's take a look at how it got there and see whether clear skies are still in the forecast.

Achillion's early stage-trial hepatitis C drug ACH-3102 gets fast-track status from the FDA.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Furiex Pharmaceuticals Inc said its partner Johnson & Johnson returned the worldwide rights for its oral drug to treat premature ejaculation.

Myrexis Inc., a Salt Lake City-based biotechnology research company that idled much of its operations last year, said it is pursing a new long-term strategy.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Board Names Richard B. Brewer President and CEO and David W. Gryska COO SALT LAKE CITY, May 11, 2012 -- Myrexis, Inc.

Myrexis announced that its Board of Directors has appointed Richard B. Brewer as President and CEO, and David W. Gryska as COO, effective May 11.

Left to right: Isobel Coleman with panelists Alex Counts of the Grameen Foundation, Ann Mei Chang of the State Department, and Scott C. Ratzan of Johnson & Johnson at a roundtable in the ExxonMobil Women and Development Series hosted by the Council on Foreign Relations on May 10, 2012 .

Johnson & Johnson is probably the most diversified of the large healthcare companies.